Condition: Neoplastic Disease · Glioblastoma · Glioblastoma Multiforme · Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Royal North Shore Hospital | Sydney, New South Wales, Australia | Recruiting |
| Gold Coast University Hospital | Gold Coast, Queensland, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Olivia Newton John Cancer Research Institute/Austin Health | Melbourne, Victoria, Australia | Recruiting |
| Institut für Nuklearmedizin und Endokrinologie | Linz, Austria | Recruiting |
| UNMC Utrecht | Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05450744